Melatomed Approval: Why the EMA Cleared the New Slow-Release Sleep Aid for Adults 55+

 (By: Medscape)

EU Regulatory Breakthrough: The Approval of Melatonin for Geriatric Insomnia

Executive Summary

In a significant move for European geriatric care, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for Melatomed (developed by Fairmed Healthcare GmbH). This generic formulation of melatonin is specifically indicated for the short-term management of primary insomnia in adults aged 55 and older.

Melatomed Approval: Why the EMA Cleared the New Slow-Release Sleep Aid for Adults 55+

The approval process was marked by a complex regulatory debate regarding bioequivalence, highlighting the stringent standards the EMA maintains for generic medications—especially those utilizing slow-release delivery systems for hormone-based therapies.

The Product: Understanding Slow-Release Melatonin

Melatomed is a generic version of the reference medicine Circadin. The active ingredient, melatonin, is a naturally occurring hormone produced by the pineal gland. It plays a foundational role in the body’s circadian rhythm, signaling to brain regions that it is time to initiate sleep.

Melatomed Approval: Why the EMA Cleared the New Slow-Release Sleep Aid for Adults 55+

Why the 55+ Demographic?

Primary insomnia—insomnia not caused by an underlying medical condition or environmental factor—is particularly prevalent in older adults. As the human body ages, the natural production of endogenous melatonin tends to decline. This "melatonin deficiency" can lead to fragmented sleep and difficulty initiating rest.

Melatomed Approval: Why the EMA Cleared the New Slow-Release Sleep Aid for Adults 55+

Unlike immediate-release melatonin, often found in over-the-counter supplements, Melatomed uses a slow-release (prolonged-release) formulation. This delivery method mimics the body’s natural secretion pattern, releasing the hormone gradually over several hours to help patients not just fall asleep, but remain asleep throughout the night.

Regulatory Journey: The Arbitration Process

The path to approval for Melatomed was not without friction. The application was submitted through a decentralized procedure, with Germany acting as the reference Member State. While Germany, Austria, and Denmark were inclined to approve the drug, Sweden raised significant objections.

Melatomed Approval: Why the EMA Cleared the New Slow-Release Sleep Aid for Adults 55+

The Bioequivalence Controversy

Sweden’s Medical Products Agency expressed concerns that Fairmed Healthcare had not sufficiently demonstrated that Melatomed was bioequivalent to Circadin. In the world of generics, "bioequivalence" means that the generic drug must be absorbed into the bloodstream at the same rate and to the same extent as the brand-name original.

Melatomed Approval: Why the EMA Cleared the New Slow-Release Sleep Aid for Adults 55+

The core of the dispute rested on two single-dose studies provided by the company:

1. Fasting Study: Conducted on an empty stomach; results were consistent with the reference drug.

2. Fed Study: Conducted after a meal. This is where the discrepancy appeared.

In the "fed" study, the Area Under the Curve (AUC)—a measurement of the total drug exposure in the body—for certain later time intervals fell outside the strictly defined acceptable ranges for bioequivalence. Sweden argued that these variations suggested the drug might not behave identically to Circadin in a real-world setting where patients take medication after dinner.

Resolution by the CHMP

The matter was referred to the CHMP for arbitration in October 2025. Upon closer inspection, the Committee determined that the "failure" in the fed study was likely a statistical artifact rather than a flaw in the drug’s formulation.

Melatomed Approval: Why the EMA Cleared the New Slow-Release Sleep Aid for Adults 55+

The EMA concluded that:

• Natural Variability: Melatonin levels fluctuate naturally in the human body, varying according to individual physiology.

• Study Design: The original studies were not powered (did not have enough participants) to account for the high degree of individual variability required for "divided interval" AUC measurements.

• Totality of Evidence: When examining the complete data set, including peak concentration (Cmax) and total absorption, the drug demonstrated sufficient equivalence with Circadin.

By ruling that the variations were due to natural daily fluctuations rather than the product itself, the CHMP cleared the way for the European Commission to issue a final decision.

Clinical Implications and Safety

The approval of a new generic in this space is expected to increase accessibility and reduce costs for healthcare systems across the EU. However, the EMA emphasizes that Melatomed is intended for short-term use (typically up to 13 weeks).

Melatomed Approval: Why the EMA Cleared the New Slow-Release Sleep Aid for Adults 55+

Benefits Over Traditional Hypnotics

For the elderly, melatonin-based treatments are often preferred over traditional "Z-drugs" (like zolpidem) or benzodiazepines. Traditional sedatives are associated with a higher risk of:

Melatomed Approval: Why the EMA Cleared the New Slow-Release Sleep Aid for Adults 55+

• Cognitive Impairment: Increased confusion or "brain fog" the following morning.

• Falls and Fractures: Impaired balance and motor coordination.

• Dependency: High potential for addiction and withdrawal symptoms.

Melatonin offers a more "physiological" approach to sleep, generally lacking the habit-forming properties and significant "hangover effect" associated with older sedative-hypnotics.

Market Outlook and Next Steps

Following the CHMP’s positive recommendation, the European Commission is expected to grant marketing authorization shortly. Once finalized, Melatomed will be available for national authorization in:

Melatomed Approval: Why the EMA Cleared the New Slow-Release Sleep Aid for Adults 55+

• Germany

• Austria

• Denmark

• Sweden

The EMA will publish a detailed Summary of Product Characteristics (SmPC), which will provide clinicians with specific dosing guidelines and a full profile of potential side effects.

Conclusion

The clearance of Melatomed represents a victory for evidence-based generic drug manufacturing. By navigating the complex bioequivalence requirements of the EMA, Fairmed Healthcare has secured a pathway to provide a critical sleep aid to an aging European population. This approval reinforces the importance of slow-release hormone therapy as a first-line pharmacological intervention for primary insomnia in seniors, balancing the need for efficacy with the paramount requirement for safety in geriatric medicine.